337 related articles for article (PubMed ID: 28465778)
41. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis.
Feldman SR; Koo JY; Johnson LA; Preston NJ
Cutis; 2009 Oct; 84(4 Suppl):25-32. PubMed ID: 19916299
[TBL] [Abstract][Full Text] [Related]
42. Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multi-stakeholder mixed methods study.
Gleeson D; Naveed M; Moorhead L; McAteer H; Sewell G; McGuire A; Weinman J; Barker JNWN; Norton S; Chapman SCE; Smith CH; Mahil SK
Br J Dermatol; 2024 Feb; ():. PubMed ID: 38366988
[TBL] [Abstract][Full Text] [Related]
43. Psoriasis and psoriatic arthritis treatment.
Menter A
Am J Manag Care; 2016 Jun; 22(8 Suppl):s225-37. PubMed ID: 27356194
[TBL] [Abstract][Full Text] [Related]
44. Prevalence and economic burden of comorbid anxiety and depression among patients with moderate-to-severe psoriasis.
Cai Q; Teeple A; Wu B; Muser E
J Med Econ; 2019 Dec; 22(12):1290-1297. PubMed ID: 31262226
[No Abstract] [Full Text] [Related]
45. Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.
Frieder J; Kivelevitch D; Menter A
Ther Deliv; 2017 Aug; 8(9):737-746. PubMed ID: 28659016
[TBL] [Abstract][Full Text] [Related]
46. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.
Kerdel F; Zaiac M
Dermatol Ther; 2015; 28(6):390-403. PubMed ID: 26258910
[TBL] [Abstract][Full Text] [Related]
47. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States.
Schaefer CP; Cappelleri JC; Cheng R; Cole JC; Guenthner S; Fowler J; Johnson S; Mamolo C
J Am Acad Dermatol; 2015 Oct; 73(4):585-593.e3. PubMed ID: 26253364
[TBL] [Abstract][Full Text] [Related]
48. Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.
Ighani A; Yu AM; Sandhu VK; Barankin B; Manolson MF
J Cutan Med Surg; 2019; 23(2):148-156. PubMed ID: 30801221
[TBL] [Abstract][Full Text] [Related]
49. Microneedles as a momentous platform for psoriasis therapy and diagnosis: A state-of-the-art review.
Gowda BHJ; Ahmed MG; Hani U; Kesharwani P; Wahab S; Paul K
Int J Pharm; 2023 Feb; 632():122591. PubMed ID: 36626973
[TBL] [Abstract][Full Text] [Related]
50. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.
Feldman SR; Wu JJ; Rastogi S; Menges B; Lingohr-Smith M; Lin J
J Med Econ; 2018 May; 21(5):537-541. PubMed ID: 29357713
[TBL] [Abstract][Full Text] [Related]
51. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
Strober B; Karki C; Mason M; Guo N; Holmgren SH; Greenberg JD; Lebwohl M
J Am Acad Dermatol; 2018 Feb; 78(2):323-332. PubMed ID: 29051036
[TBL] [Abstract][Full Text] [Related]
52. Disease burden and treatment adherence in psoriasis patients.
Feldman SR
Cutis; 2013 Nov; 92(5):258-63. PubMed ID: 24343214
[TBL] [Abstract][Full Text] [Related]
53. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.
Lebwohl MG; Bachelez H; Barker J; Girolomoni G; Kavanaugh A; Langley RG; Paul CF; Puig L; Reich K; van de Kerkhof PC
J Am Acad Dermatol; 2014 May; 70(5):871-81.e1-30. PubMed ID: 24576585
[TBL] [Abstract][Full Text] [Related]
54. Diagnosis and management of psoriasis.
Kim WB; Jerome D; Yeung J
Can Fam Physician; 2017 Apr; 63(4):278-285. PubMed ID: 28404701
[TBL] [Abstract][Full Text] [Related]
55. The psychosocial burden of psoriasis.
Kimball AB; Jacobson C; Weiss S; Vreeland MG; Wu Y
Am J Clin Dermatol; 2005; 6(6):383-92. PubMed ID: 16343026
[TBL] [Abstract][Full Text] [Related]
56. Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data.
Armstrong AW; Koning JW; Rowse S; Tan H; Mamolo C; Kaur M
Dermatol Ther (Heidelb); 2017 Mar; 7(1):97-109. PubMed ID: 27905011
[TBL] [Abstract][Full Text] [Related]
57. Psoriasis.
Burfield L; Burden AD
J R Coll Physicians Edinb; 2013; 43(4):334-8; quiz 339. PubMed ID: 24350319
[TBL] [Abstract][Full Text] [Related]
58. Optimizing Secukinumab Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report.
Kostaki D; Aquila E; Macaluso L; Mattozzi C; Richetta AG
Case Rep Dermatol; 2019; 11(Suppl 1):17-22. PubMed ID: 31662734
[TBL] [Abstract][Full Text] [Related]
59. Infliximab in psoriasis and psoriatic arthritis.
Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
[TBL] [Abstract][Full Text] [Related]
60. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.
Crown WH; Bresnahan BW; Orsini LS; Kennedy S; Leonardi C
Curr Med Res Opin; 2004 Dec; 20(12):1929-36. PubMed ID: 15701211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
